Share-based Payment Arrangement, Expense of CRESCENT BIOPHARMA, INC. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CRESCENT BIOPHARMA, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • CRESCENT BIOPHARMA, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,985,000, a 2777% increase year-over-year.
  • CRESCENT BIOPHARMA, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $9,959,572.
  • CRESCENT BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2024 was $4,697,546, a 33% increase from 2023.
  • CRESCENT BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2023 was $3,524,476, a 8.6% decline from 2022.
  • CRESCENT BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2022 was $3,857,580, a 37% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

CRESCENT BIOPHARMA, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,959,572 $1,985,000 +$1,916,000 +2777% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $8,043,572 $5,340,000 +$4,132,678 +342% 01 Apr 2025 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $3,910,894 $405,428 -$786,652 -66% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $4,697,546 $2,229,144 +$1,320,773 +145% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $69,000 -$818,837 -92% 20 Sep 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $3,376,773 $1,138,115 +$250,278 +28% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $4,195,610 $1,207,322 +$349,234 +41% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $3,846,376 $1,192,080 +$321,900 +37% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $3,524,476 $908,371 +$9,170 +1% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $3,515,306 $887,837 -$26,142 -2.9% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $3,541,448 $858,088 -$105,670 -11% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $3,647,118 $870,180 -$210,462 -19% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $3,857,580 $899,201 -$420,880 -32% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $4,278,460 $913,979 -$676,880 -43% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $4,955,340 $963,758 -$598,403 -38% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $5,553,743 $1,080,642 -$533,543 -33% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $6,087,286 $1,320,081 -$307,505 -19% 01 Oct 2021 31 Dec 2021 10-K 27 Mar 2024 2023 FY
Q3 2021 $6,394,791 $1,590,859 -$99,492 -5.9% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $6,494,283 $1,562,161 -$199,512 -11% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $6,693,795 $1,614,185 -$207,963 -11% 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022 2022 Q1
Q4 2020 $6,901,758 $1,627,586 -$98,519 -5.7% 01 Oct 2020 31 Dec 2020 10-K 29 Mar 2023 2022 FY
Q3 2020 $7,000,277 $1,690,351 +$103,204 +6.5% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $6,897,073 $1,761,673 +$242,278 +16% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $6,654,795 $1,822,148 +$439,705 +32% 01 Jan 2020 31 Mar 2020 10-Q 03 May 2021 2021 Q1
Q4 2019 $6,215,090 $1,726,105 +$576,349 +50% 01 Oct 2019 31 Dec 2019 10-K 03 Mar 2022 2021 FY
Q3 2019 $5,638,741 $1,587,147 +$416,024 +36% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $5,222,717 $1,519,395 +$369,006 +32% 01 Apr 2019 30 Jun 2019 10-Q 31 Jul 2020 2020 Q2
Q1 2019 $4,853,711 $1,382,443 +$266,613 +24% 01 Jan 2019 31 Mar 2019 10-Q 01 May 2020 2020 Q1
Q4 2018 $4,587,098 $1,149,756 +$185,254 +19% 01 Oct 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
Q3 2018 $4,401,844 $1,171,123 +$208,778 +22% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $4,193,066 $1,150,389 +$159,281 +16% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $4,033,785 $1,115,830 +$272,983 +32% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $3,760,802 $964,502 +$238,382 +33% 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
Q3 2017 $3,522,420 $962,345 +$222,932 +30% 01 Jul 2017 30 Sep 2017 10-Q 02 Nov 2018 2018 Q3
Q2 2017 $3,299,488 $991,108 +$219,421 +28% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $3,080,067 $842,847 +$115,300 +16% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018 2018 Q1
Q4 2016 $2,964,767 $726,120 +$81,185 +13% 01 Oct 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
Q3 2016 $2,883,582 $739,413 +$106,489 +17% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $2,777,093 $771,687 +$313,457 +68% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $2,463,636 $727,547 +$140,033 +24% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $2,323,603 $644,935 +$162,291 +34% 01 Oct 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
Q3 2015 $2,161,312 $632,924 +$191,148 +43% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3
Q2 2015 $1,970,164 $458,230 +$39,801 +9.5% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $1,930,363 $587,514 +$295,298 +101% 01 Jan 2015 31 Mar 2015 10-Q 04 May 2016 2016 Q1
Q4 2014 $1,635,065 $482,644 +$422,035 +696% 01 Oct 2014 31 Dec 2014 10-K 01 Mar 2017 2016 FY
Q3 2014 $1,213,030 $441,776 +$294,370 +200% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $918,660 $418,429 +$308,766 +282% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015 2015 Q2
Q1 2014 $609,894 $292,216 +$184,205 +171% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015 2015 Q1
Q4 2013 $425,689 $60,609 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $147,406 01 Jul 2013 30 Sep 2013 10-Q 31 Oct 2014 2014 Q3
Q2 2013 $109,663 01 Apr 2013 30 Jun 2013 10-Q 31 Jul 2014 2014 Q2
Q1 2013 $108,011 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1

CRESCENT BIOPHARMA, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,697,546 +$1,173,070 +33% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $3,524,476 -$333,104 -8.6% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $3,857,580 -$2,229,706 -37% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $6,087,286 -$814,472 -12% 01 Jan 2021 31 Dec 2021 10-K 27 Mar 2024 2023 FY
2020 $6,901,758 +$686,668 +11% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2023 2022 FY
2019 $6,215,090 +$1,627,992 +35% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2022 2021 FY
2018 $4,587,098 +$826,296 +22% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
2017 $3,760,802 +$796,035 +27% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $2,964,767 +$641,164 +28% 01 Jan 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
2015 $2,323,603 +$688,538 +42% 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
2014 $1,635,065 +$1,209,376 +284% 01 Jan 2014 31 Dec 2014 10-K 01 Mar 2017 2016 FY
2013 $425,689 +$10,481 +2.5% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $415,208 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.